Ramsay Générale de Santé stock
GDS.PAPARRamsay Générale de Santé S.A., HealthcareISIN FR0000044471
39Score 39 out of 100, Weak
Price and trend
34 / 100
Price history
−4.5% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 18% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 32).
The price is 26% below its 52-week high. Largest decline in 20 years: 79% (May 2007 to October 2008).
Chart figures for advanced users
- SMA 50$10.78
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$11.64
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)32
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$9.52
- The lowest closing price of the last twelve months.
- Resistance$12.80
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Ramsay Générale de Santé S.A. belongs to the Medical (Care Facilities) industry (France) and, with a market value of $1.05B, is number 45 of 56 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $5.99B (up 2.7% year on year) and a loss of $53.74M.
- MEQIRI Score 39 out of 100 (Weak): rank 564 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Share buybacksShare count down 6% since 2020.
Weaknesses
- High debtDebt 3.49 times equity (latest quarter), Medical (Care Facilities) median 0.96.Stability 30
- Interest barely coveredOperating profit covers interest only 1 times.Stability 30
- Loss-makingLoss of $53.74M over the last 12 months.Fundamentals 57
Its standout strength is valuation, while growth and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 40 to 39.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
Valuation
Valuation signal
Possible value trapClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Possible value trap: looks cheap, but score below 50, high risk, weak growth.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 2.7% on the prior year. Revenue has grown solidly since 2006, at about 6% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 79%, operating 4%, net −1%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- No date announced.
- Last reported
- 25 Feb 2026EPS reported −$0.36
Sector comparison
714 rated companies in Healthcare
- This company
- 39
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Nutex HealthNUTX $1.3B74
- Innovage HoldingINNV $1.3B59
- Pennant GroupPNTG $1.29B54
- RHÖN-KLINIKUMRHK.DE $1.09B57
- Clínica BavieraCBAV.MC $938.33M80
- TerveystaloTTALO.HE $873.42M51
- GMR SolutionsGMRS $635.3M57
- Strata Critical MedicalSRTA $536.81M47
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 30 Jun 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 3 Jul 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.